Talphera Inc (TLPH)

Jan 14, 2025

FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 14, 2025

FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria

Jan 14, 2025

Jan 14, 2025

FDA to review Talphera's request to amend NEPHRO study - Investing.com

Jan 14, 2025

Jan 14, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - Marketscreener.com

Jan 14, 2025

Dec 26, 2024

TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK

Dec 26, 2024

Dec 17, 2024

TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com

Dec 17, 2024

Dec 12, 2024

Talphera faces Nasdaq delisting over share price rule - Investing.com

Dec 12, 2024

Dec 11, 2024

Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK

Dec 11, 2024

Dec 11, 2024

Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com

Dec 11, 2024

Dec 07, 2024

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 - Kilgore News Herald

Dec 07, 2024

Dec 06, 2024

Talphera CEO Vincent J. Angotti acquires $3,199 in common stock - Investing.com

Dec 06, 2024

Dec 06, 2024

Talphera CEO Vincent J. Angotti acquires $3,199 in common stock By Investing.com - Investing.com UK

Dec 06, 2024

Dec 02, 2024

Talphera CEO Vincent J. Angotti buys $3,649 in company stock By Investing.com - Investing.com Canada

Dec 02, 2024

Dec 02, 2024

Talphera CFO Raffi Asadorian sells shares worth $118 - Investing.com India

Dec 02, 2024

Dec 02, 2024

Talphera CEO Vincent J. Angotti buys $3,649 in company stock - Investing.com India

Dec 02, 2024

Dec 02, 2024

Talphera CFO Raffi Asadorian sells shares worth $118 By Investing.com - Investing.com Canada

Dec 02, 2024

Nov 16, 2024

Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023) - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Talphera (FRA:R5XA) Inventories, Raw Materials & Components : €0.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

Talphera: Q3 Earnings Snapshot - mySA

Nov 14, 2024

Nov 13, 2024

Talphera Reports Q3 2024 Results and Study Progress - TipRanks

Nov 13, 2024

Nov 13, 2024

Talphera's Q3 Loss Widens to $3.4M as NEPHRO Trial Expands to New Sites | TLPH Stock News - StockTitan

Nov 13, 2024

Nov 13, 2024

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Nov 13, 2024

Nov 12, 2024

An Overview of Talphera's Earnings - Benzinga

Nov 12, 2024

Nov 06, 2024

Talphera Sets Q3 2024 Earnings Call for November 13Key Financial Results Update | TLPH Stock News - StockTitan

Nov 06, 2024

Oct 28, 2024

Talphera, Inc. (NASDAQ:TLPH) Sees Large Decline in Short Interest - Defense World

Oct 28, 2024

Oct 09, 2024

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - Citizentribune

Oct 09, 2024

Oct 02, 2024

Talphera extends agreement deadline with Nantahala Management By Investing.com - Investing.com Australia

Oct 02, 2024

Oct 01, 2024

Talphera extends agreement deadline with Nantahala Management - Investing.com

Oct 01, 2024

Sep 05, 2024

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald

Sep 05, 2024

Sep 03, 2024

Talphera CEO Vincent J. Angotti buys $7.6k in company stock - Investing.com

Sep 03, 2024

Sep 02, 2024

Credit Suisse gives an Underperform recommendation for Talphera Inc. (TLPH) - Knox Daily

Sep 02, 2024

Aug 21, 2024

TLPH Stock Earnings: Talphera Beats EPS for Q2 2024 - MSN

Aug 21, 2024

Aug 19, 2024

Talphera starts key trial for anticoagulant nafamostat - Investing.com India

Aug 19, 2024

Aug 19, 2024

Talphera starts key trial for anticoagulant nafamostat By Investing.com - Investing.com Canada

Aug 19, 2024

Aug 19, 2024

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit - PR Newswire

Aug 19, 2024

Aug 17, 2024

Talphera First Half 2024 Earnings: US$0.31 loss per share (vs US$0.40 loss in 1H 2023) - Yahoo Finance

Aug 17, 2024

Aug 16, 2024

Talphera Inc (TLPH) Q2 2024 Earnings Call Transcript Highlights: Strategic Advancements and Financial Adjustments - GuruFocus.com

Aug 16, 2024

Aug 15, 2024

Talphera: Q2 Earnings Snapshot - San Antonio Express-News

Aug 15, 2024

Aug 15, 2024

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update - Longview News-Journal

Aug 15, 2024

Aug 14, 2024

Talphera, Inc. (NASDAQ:TLPH) Q2 2024 Earnings Call Transcript - MSN

Aug 14, 2024

Aug 14, 2024

Talphera Announces CMO Retirement and Successor Appointment - TipRanks

Aug 14, 2024